A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.

Key facts

Study ID

NCT01525589

Run by

PharmaMar

People needed

111

Starts

2012-06-13

Expected to finish

2018-10-01

Last updated by the study team

2020-09-25

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women ≥ 18 and ≤ 75 years of age.
• Voluntary signed informed consent form (ICF).
• Proven diagnosis of metastatic breast cancer (MBC).
• At least one, but no more than three, prior chemotherapy regimens for MBC.
• Patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.
• Disease evaluable for response by specific appropriate criteria.
• No or minimal disease-related symptoms not affecting patient daily activities.
• Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)
• Wash out periods prior to Day 1 of Cycle 1:
• At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/investigational therapy
• Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.
• Patients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.
• Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)
• Prior treatment with PARP inhibitors (Patients in Cohort A1)

You may not qualify if…

• Prior treatment with PM01183 or trabectedin.
• Extensive prior RT.
• Prior or concurrent malignant disease unless cured for more than five years.
• Exceptions are breast cancer in the other breast.
• Uncommon or rare subtypes of breast cancer.
• Symptomatic or progressive brain metastases.
• Bone-limited and exclusively metastases.
• Relevant diseases or clinical situations which may increase patient's risk:
• History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV).
• Known muscular disease or functional alteration
• Pregnant or breastfeeding women.
• Impending need for immediate RT for symptomatic relief.
• Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.

Where it is running

• Stanford Women's Cancer Center — Stanford, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York, United States
• Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Complexo Hospitalario Universitario A Coruña — A Coruña, A Coruña, Spain
• Complexo Hospitalario Universitario de Santiago — Santiago de Compostela, A Coruña, Spain
• Hospital Universitari Vall d'Hebron — Barcelona, Spain
• Hospital Clínico Universitario de Valencia — Valencia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.